In particular, 20 to 30% of breast cancers are classified as human epidermal growth factor 2 (HER2) positive and have aggressive biological characteristics compared to other breast cancer subtypes, reducing overall survival [1,2]. Here, ERBB2 is linked to breast carcinoma.